Antiseizure Medications: Mechanisms, Epilepsy Syndromes, Pregnancy and Monitoring

Medical education review updated 10 November 2026. Information is educational; treatment requires individualized clinical assessment and locally approved products.

Overview

Antiseizure medications (ASMs) reduce seizure recurrence through modulation of neuronal excitability or synaptic transmission. A drug that treats focal seizures may worsen some generalized epilepsies, so selection begins with seizure type, epilepsy syndrome, age, comorbidities, interactions and pregnancy potential. A medication does not automatically cure epilepsy; decisions to taper after long-term seizure freedom require individualized specialist assessment [1,2].

Classification by mechanism

  • Voltage-gated sodium channels: carbamazepine, oxcarbazepine, phenytoin, lamotrigine and lacosamide; lacosamide preferentially enhances slow inactivation, unlike many older agents.
  • SV2A ligands: levetiracetam and brivaracetam regulate synaptic vesicle release.
  • GABA enhancement: benzodiazepines increase the frequency of GABA-A channel opening in the presence of GABA; phenobarbital prolongs opening duration, while vigabatrin inhibits GABA transaminase and tiagabine inhibits GABA uptake.
  • Calcium-channel effects: ethosuximide reduces thalamic T-type calcium currents and is useful for typical absence seizures; gabapentin and pregabalin bind alpha2delta auxiliary subunits, not GABA receptors.
  • Multiple mechanisms: valproate, topiramate, zonisamide and others affect several targets [1].

Syndrome-directed treatment

Focal epilepsy often responds to lamotrigine, levetiracetam and selected sodium-channel agents. Typical childhood absence seizures may be treated with ethosuximide where other generalized seizure types are absent. Generalized tonic-clonic seizures require broad-spectrum choices adapted to syndrome and reproductive risk. Carbamazepine and oxcarbazepine may exacerbate absence or myoclonic seizures. Rescue benzodiazepines and emergency protocols treat prolonged seizures or status epilepticus, while maintenance doses should not be improvised from acute regimens [1].

Pregnancy and reproductive safety

The 2024 AAN/AES/SMFM guideline favors consideration of lamotrigine, levetiracetam or oxcarbazepine where clinically suitable to minimize major congenital malformations, and avoiding valproate when feasible because of congenital and neurodevelopmental risks. It recommends at least 0.4 mg/day folic acid before and during pregnancy for patients taking ASMs. Lamotrigine and levetiracetam clearance may increase during pregnancy, requiring individualized levels and dose review. Do not abruptly discontinue an effective ASM after pregnancy recognition, because convulsive seizures are dangerous [2].

Adverse effects and interactions

Carbamazepine, phenytoin and phenobarbital induce metabolic enzymes and can compromise hormonal contraceptive efficacy. Valproate inhibits metabolism of lamotrigine and raises severe rash risk unless titration is adjusted. Carbamazepine and oxcarbazepine can cause hyponatremia; phenytoin has nonlinear kinetics, gingival overgrowth and ataxia; levetiracetam may contribute to behavioral symptoms; lamotrigine can cause severe rash including Stevens–Johnson syndrome. Monitor CBC, sodium, liver/kidney function, bone health or drug levels according to agent, not universally [1,2].

Emergency warning and monitoring

Seizures lasting five minutes or repeated seizures without recovery require emergency response. Patients should receive counseling on adherence, sleep, driving restrictions, SUDEP risk and a rescue plan when appropriate. Individual drug labels, regional availability and specialist guidance remain essential [1].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. Pack AM, Oskoui M, et al. Teratogenesis, perinatal, and neurodevelopmental outcomes after in utero exposure to antiseizure medication: AAN/AES/SMFM practice guideline. Neurology. 2024. Available from: https://pubmed.ncbi.nlm.nih.gov/38748979/
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *